Evidence-based treatment of eating disorders

Current Opinion in Pediatrics

Volumn 14, Issue 4, 2002, Pages 379-383

  Rosenblum, Jennifer ^a   Forman, Sara ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; ESTROGEN; FLUOXETINE; GESTAGEN; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OLANZAPINE; PHENELZINE; PRASTERONE; RECOMBINANT SOMATOMEDIN C; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADOLESCENT; ANOREXIA NERVOSA; BEHAVIOR THERAPY; BULIMIA; CLINICAL TRIAL; COGNITIVE THERAPY; DRUG EFFICACY; EATING DISORDER; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; EXERCISE; HUMAN; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW;

ADOLESCENT; ADULT; ANOREXIA NERVOSA; BULIMIA; EVIDENCE-BASED MEDICINE; HUMANS;

EID: 0036063513     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200208000-00003     Document Type: Review

References (59)

1. Cognitive-behavioral therapy for binge eating and bulimia nervosa: A comprehensive treatment manual
2. Psychotherapy for bulimia nervosa and binging
3. Cognitive-behavioral treatment with and without response prevention for bulimia
4. Comparison of cognitive-behavioral and supportive-expressive therapy for bulimia nervosa
5. A prospective study of outcome in bulimia nervosa and the long-term effects of three psychological treatments
6. Cognitive therapy, nutritional therapy and their combination in the treatment of bulimia nervosa
7. Cognitive-behavioral therapy for bulimia: An initial outcome study
8. Cognitive-behavioral treatment of bulimia nervosa: A controlled evaluation
9. Psychotherapy for bulimia: A controlled study
10. Bulimia nervosa: A meta-analysis of psychosocial and pharmacological treatments
11. Antidepressants versus placebo for people with bulimia nervosa
12. A placebo-controlled, double-blind trial of amitriptyline in bulimia
13. Treatment of bulimia with fenfluramine and desipramine
14. Treating bulimia with desipramine: A double-blind, placebo-controlled study
15. A double-blind trial of phenelzine in bulimia
16. Fluoxetine plus naltrexone in the treatment of bulimia nervosa
17. A comparative trial: Cognitive behavioral therapy, fluoxetine, and a combination in the treatment of DSM-III-R bulimia nervosa
18. Long-term fluoxetine treatment of bulimia nervosa
19. Fluoxetine in bulimia following failure of psychotherapy
20. Intensive nutritional counseling in bulimia nervosa: A role for supplementation with fluoxetine?
21. Pharmacotherapy of bulimia nervosa with fluoxetine: Assessment of clinically significant attitudinal change
22. Fluvoxamine in prevention of relapse in bulimia nervosa: Effects on eating-specific psychopathology
23. Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa
24. Fluoxetine and cognitive behavioral therapy for anorexia nervosa: A multi-center treatment study
25. Sertraline in the treatment of restricting anorexia nervosa: An open controlled trial
26. Venlafaxine versus fluoxetine in the treatment of atypical anorectic outpatients: A preliminary study
27. Does fluoxetine augment the inpatient treatment of anorexia nervosa?
28. Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa
29. Olanzapine in children and adolescents with chronic anorexia nervosa: A study of five cases
30. Case reports of olanzapine treatment of anorexia nervosa
31. Anorexia nervosa: Treatment with olanzapine
32. Risperidone in anorexia nervosa
33. Olanzapine in the treatment of anorexia nervosa
34. Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders: Anorexia nervosa-binge-eating/purging type
35. Combined cognitive-behavioral, psychopharmacological and nutritional therapy in eating disorders: Anorexia nervosa-restricted type
36. Combined cognitive-behavioral, psychopharmacological and nutritional therapy in bulimia nervosa
37. Pharmacologic and cognitive-behavioral treatment for bulimia nervosa: A controlled comparison
38. A randomized controlled trial of fluoxetine and cognitive behavioral therapy for bulimia nervosa: Short-term outcome
39. Review: Medication and cognitive behavior therapy control symptoms of bulimia nervosa
40. Antidepressants versus psychological treatments and their combination for bulimia nervosa
41. Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa
42. The effects of anorexia nervosa on bone metabolism in female adolescents
43. Severity of osteopenia in estrogen-deficient women with anorexia nervosa and hypothalamic amenorrhea
44. Mechanisms and treatment options for bone loss in anorexia nervosa
45. Osteoporosis in eating disorders: A follow-up study of patients with anorexia and bulimia nervosa
46. Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa
47. Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa
48. Relation of bone density to estradiol and cortisol in anorexia nervosa and bulimia
49. DHEA and the skeleton (through the ages)
50. Changes in bone turnover markers and menstrual function after short-term oral DHEA in young women with anorexia nervosa
51. Bone size and volumetric density in women with anorexia nervosa receiving estrogen replacement therapy and in women recovered from anorexia nervosa
52. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa
53. Osteoporosis in anorexia nervosa: The influence of peak bone density, bone loss, oral contraceptive use, and exercise
54. The role of physical activity in the development and maintenance of eating disorders
55. Osteoporotic stress fractures in anorexia nervosa: Etiology, diagnosis, and review of four cases
56. Osteoporosis in women with eating disorders: Comparison of physical parameters, exercise, and menstrual status with SPA and DPA evaluation